CoLucid Pharmaceuticals to Present Corporate Overview at the Cowen & Company 36th Annual Health Care Conference
03 mars 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at...
CoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights
02 mars 2016 16h23 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., March 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the fourth quarter and year ended December 31,...
CoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTAN
01 mars 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., March 01, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product...
CoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan
23 févr. 2016 08h11 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Feb. 23, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product...
CoLucid Pharmaceuticals to Present Corporate Overview at the BIO CEO & Investor Conference
02 févr. 2016 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at...
CoLucid Pharmaceuticals and IMS Health Publish White Paper to Address Migraine Market Misperceptions
05 janv. 2016 07h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, MA, Jan. 05, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
CoLucid Pharmaceuticals Announces Appointment of Dr. Raymond Skwierczynski as Head, Pharmaceutical Operations
08 déc. 2015 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Dec. 8, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate,...
CoLucid Pharmaceuticals Provides SAMURAI Enrollment Update
30 nov. 2015 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that over 50% of the migraine patients needed to complete the Company's SAMURAI trial,...
CoLucid Pharmaceuticals to Present Corporate Overview at the Stifel 2015 Healthcare Conference
12 nov. 2015 09h30 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today announced that Thomas Mathers, Chief Executive Officer, will present a corporate overview at the...
CoLucid Pharmaceuticals Announces Third Quarter 2015 Results and Corporate Highlights
10 nov. 2015 08h00 HE
|
CoLucid Pharmaceuticals, Inc
CAMBRIDGE, Mass., Nov. 10, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (NASDAQ:CLCD) today reported financial and operating results for the third quarter ended September 30,...